Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
…
13,692€
-3,12%
Echtzeit-Aktienkurs Catalyst Pharmaceuticals
Bid:
Ask:
Nachrichten zur Catalyst Pharmaceuticals Aktie
GNW-Adhoc: Santheras Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten
^* AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für die Behandlung von…
GNW-Adhoc: Santheras Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten
^* AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für dieBehandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten…
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the…
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage…
Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamrees Launch
…
Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk
…
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
CORAL GABLES, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today…
Catalyst Pharmaceuticals stock plummets on 10M share Spot Secondary priced at $15
…
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX)…
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX)…
GigaCloud Technology Stock, Catalyst Pharma And Knife River Among A Dozen New Stocks On IBD Watchlists
GigaCloud Technology stock, Catalyst Pharmaceuticals, Knife River and Fluence Energy are among the 12 new stocks on IBD watchlists Tuesday.…
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of Americas Most Successful Small-Cap Companies
Catalyst Ranked #4 on the List Catalyst Ranked #4 on the List…
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2023 Earnings Call Transcript
…
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio…
Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity
…
Catalyst Pharmaceuticals Partners with Sofies Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage…
GNW-Adhoc: Santhera erhält die U.S. FDA-Zulassung für AGAMREE® (Vamorolon) zur Behandlung von Duchenne-Muskeldystrophie
^Ad-hoc-Mitteilung gemäss Art. 53 KR * Die amerikanische Zulassungsbehörde FDA hat AGAMREE® (Vamorolon) für die …
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
Patrick J. McEnany to Retire as CEO and will Continue to Serve as Catalysts Chairman Patrick J. McEnany to Retire…
3 Solid Stocks to Buy for Superb Earnings Acceleration
Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.…
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage…
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical…
Catalyst Pharmaceuticals launches $500M mixed shelf offering - filing
…
5 Analysts Have This to Say About Catalyst Pharmaceuticals
Latest Ratings for CPRX
DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Mar 2021Roth CapitalMaintainsBuy Aug 2020Truist SecuritiesMaintainsBuy
…
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of 32% and 7.35%, respectively, for the quarter ended June 2023. Do the…
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22%…
Form 10-Q CATALYST PHARMACEUTICALS For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K CATALYST PHARMACEUTICALS For: Jul 24
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Catalyst Pharma announces retirement of CEO
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Catalyst Pharmaceuticals: Patrick McEnany to Retire as CEO by Year-End >CPRX
Catalyst Pharmaceuticals: Patrick McEnany to Retire as CEO by Year-End >CPRX...…
Form 8-K CATALYST PHARMACEUTICALS For: Jul 18
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy...…
Santhera schliesst Lizenzabkommen für Produktkandidaten Vamorolone ab
Biotechnologie - Das Biotechunternehmen Santhera hat den bereits vor einem Monat angekündigten Lizenzvertrag mit Catalyst Pharmaceuticals nun abgeschlossen....…
Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone
Ad hoc announcement pursuant to Art. 53 LR...…
Santhera schliesst exklusives Lizenzabkommen mit Catalyst Pharmaceuticals für Vamorolone in Nordamerika ab
Ad-hoc-Mitteilung gemäss Art. 53 KR...…
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $12.66, moving -0.78% from the previous trading session....…
Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $13.53, marking a +1.42% move from the previous day....…
Form 8-K CATALYST PHARMACEUTICALS For: Jun 19
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Is the Options Market Predicting a Spike in Catalyst Pharmaceuticals (CPRX) Stock?
Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately....…
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular…
Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties
Ad hoc announcement pursuant to Art. 53 LR...…
Form 8-K CATALYST PHARMACEUTICALS For: Jun 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million...…
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
When evaluating investments, it helps to keep quarterly performance in context....…
Insiderhandel: President and CEO verkauft Aktien von Catalyst Pharmaceuticals im Wert von 345.978$
Mcenany, Patrick J. - Vorstand - Tag der Transaktion: 2023-05-15...…
Zacks.com featured highlights include Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum
Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum are part of the Zacks Screen of the…
Implied Volatility Surging for Catalyst Pharmaceuticals (CPRX) Stock Options
Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately....…
Catalyst Pharmaceuticals: Q1 Earnings Insights
read more...…